Winning the Battle, but Losing the War: Mechanisms and Morphology of Cancer Therapy-Associated Cardiovascular Toxicity

In the United States, the lifetime risk of a cancer diagnosis is nearly 40%; in 2016 that represents almost 1.6 million new patients, and despite advances in early diagnosis and treatment, roughly 35% will ultimately die of their malignancy. Fortunately, the number of patients living with a cancer diagnosis also continues to expand, anticipated to be more than 19 million in less than a decade. In calculating the relative risks and benefits of therapy it is therefore important to consider the morbidity and mortality associated with anti-tumor therapy itself.

Source: Cardiovascular Pathology - June 30, 2017 Category: Cardiology Authors: Carolyn Kwak Glass, Richard N. Mitchell Source Type: research